EAU 2026 非肌层浸润性膀胱癌指南更新摘要
本文为2026年EAU非肌层浸润性膀胱癌(TaT1及原位癌)指南更新摘要,基于MEDLINE、EMBASE和Cochrane Library的结构化文献评估制定推荐。更新包括新增膀胱癌危险因素与进展预后因素表、BCG无应答肿瘤治疗选项表、BCG初治高危患者联合免疫检查点抑制剂新章节、尿液标志物随访表及务实降阶策略新章节。
要点
- 强调NMIBC患者的充分诊断、治疗和随访,并依据风险分层实施个体化治疗。
- 新增BCG无应答肿瘤治疗选项表及BCG初治高危患者联合免疫检查点抑制剂章节。
- 新增尿液标志物在随访中作用的表格及NMIBC务实降阶策略新章节。
核心结论
- 2026 EAU NMIBC指南提供危险因素、诊断、分类、预后因素、治疗和随访的推荐,旨在有效整合入临床实践。
研究设计与样本
- 通过结构化文献评估,检索MEDLINE、EMBASE和Cochrane Library,由专家组制定推荐,推荐强度基于利弊平衡、证据质量及患者价值观偏好确定。
主要发现
- 新增两个表格涉及膀胱癌危险因素和亚型进展预后因素。
- 新增两个表格总结BCG无应答肿瘤的治疗选项。
- 新增章节讨论在选定高危和极高危BCG初治NMIBC患者中BCG联合免疫检查点抑制剂。
- 新增表格讨论尿液标志物在随访中的作用,并新增NMIBC务实降阶策略章节。
临床怎么用
- 临床应依据风险分层对NMIBC患者进行充分诊断、治疗和随访,并参考新增表格和章节管理BCG无应答及BCG初治高危患者。
局限性
- 本文为指南摘要,信息限于尿路上皮癌(除非特别说明),未报告具体证据等级或推荐强度细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: This publication represents a summary of the updated 2026 European Association of Urology (EAU) Guidelines for nonmuscle-invasive bladder cancer (NMIBC), TaT1 and carcinoma in situ (CIS). The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC, with a focus on clinical presentation. METHODS: For the 2026 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included MEDLINE, EMBASE, and the Cochrane Library. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. KEY FINDINGS AND LIMITATIONS: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients' risk stratification and treating them appropriately. Key updates in the 2026 NMIBC Guidelines summary include: the addition of two new tables addressing risk factors for bladder cancer and prognostic factors for progression in subtypes; the addition of two new tables summarising the treatment options for Bacillus Calmette-Guérin (BCG)-unresponsive tumours; inclusion of a new section addressing the addition of immune checkpoint inhibitors to BCG in selected high- and very high-risk NMIBC BCG-NAÏVE patients; a new table addressing the role of urinary markers in follow-up; and the addition of a new section on pragmatic de-intensification strategy for NMIBC. CONCLUSIONS AND CLINICAL IMPLICATIONS: This overview of the 2026 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. They are designed for effective integration into clinical practice. PATIENT SUMMARY: The EAU has issued updated clinical practice guidelines on NMIBC. The guidelines provide recommendations for diagnosis, treatment, and follow-up, with a particular focus on quality of life for patients.
引用
- Gontero P, Mariappan P, Pradere B, et al. EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update. Eur Urol. 2026. PMID: 42457459. doi:10.1016/j.eururo.2026.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。